Racial and Ethnic Disparities and Health Inequities in Multiple Myeloma

This activity is part of a series

Faculty

Edith Peterson Mitchell, MD, MACP, FCPP, FRCP
Clinical Professor of Medicine and Medical Oncology Department of Medical Oncology
Director, Center to Eliminate Cancer Disparities Associate Director, Diversity Affairs
Sidney Kimmel Cancer Center at Jefferson Philadelphia, PA 116th President of the National Medical Ass
Edith Peterson Mitchell, MD, MACP, FCPP, FRCP

Edith Peterson Mitchell, MD, MACP, FCPP, FRCP, is board certified in Internal Medicine and Medical Oncology and is Clinical Professor of Medicine and Medical Oncology at Sidney Kimmel Medical College at Thomas Jefferson University and Associate Director for Diversity Programs and Director of the Center to Eliminate Cancer Disparities for Sidney Kimmel Cancer Center at Jefferson.

Dr. Mitchell has spent her medical career helping individuals in medically underserved areas and has demonstrated the importance of community service and outreach, especially to underserved populations. Her research in breast, colorectal, and pancreatic cancers and other GI malignancies involves new drug evaluation and chemotherapy, development of new therapeutic regimens, chemoradiation strategies for combined-modality therapy, patient selection criteria, and supportive care for patients with gastrointestinal cancer.

Dr. Mitchell served as the 116th President of the National Medical Association, and is a member of the American Medical Association, National Medical Association, Aerospace Medical Association, Association of Military Surgeons, Medical Society of Eastern Pennsylvania, ECOG/ACRIN Cancer Research Group, and Radiation Therapy Oncology Group. Because of her experience in the cancer research community, Dr. Mitchell served as a member of the National Cancer Institute Blue Ribbon Panel convened to advise the National Cancer Advisory Board on then Vice President Biden’s National Cancer Moonshot Initiative. In 2019, Dr. Mitchell began service as a member of the President’s Cancer Panel. In 2020, she became a Fellow of the Royal College of Physicians.

In addition to her medical achievements, Dr. Mitchell is a retired United States Air Force Brigadier General.

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute (TGen), Phoenix, AZ
Chief Medical Officer, International Myeloma Foundation (IMF), Studio City, CA
Joseph Mikhael, MD, MEd, FRCPC, FACP

Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF).

Dr. Mikhael is a consultant hematologist and Director of Myeloma Research at the HonorHealth Research Institute where he conducts phase 1 clinical trials. He also serves as a Councilor on the Executive of the American Society of Hematology. Dr. Mikhael is the Chair of the Diversity, Equity and Inclusion Council for TGen.

Dr. Mikhael was recently a hematologist at Mayo Clinic Arizona where he served as a Professor at the Mayo College of Medicine, Associate Dean of Graduate Medical Education and Deputy Director – Education of the Mayo Clinic Cancer Center. He has been recognized with numerous awards in education including being in the Mayo Clinic Resident and Fellow Association Hall of Fame as Educator of the Year. He was also recently named in the Top 100 Doctors in the United States.

Dr. Mikhael did his initial medical school training in Ottawa, Canada, followed by his Hematology Residency at Princess Margaret Hospital in Toronto. He then did a Multiple Myeloma Fellowship there along with a Masters’ Degree in Education from the University of Toronto. He was on staff at PMH until being recruited to Mayo Clinic in 2008.

He specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom’s macroglobulinemia. Dr. Mikhael is currently the principal investigator of many clinical trials, primarily in multiple myeloma. His other clinical research interests also include pharmaco-economics, communication skills and media relations. He has published over 150 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group and led the first ever ASCO Guidelines for Multiple Myeloma.

Dr. Mikhael leads the diversity efforts of the IMF, known as the M-Power program, seeking to empower patients and communities change the course of myeloma in at risk populations. He is also leading the IMF African American initiative whose goal is to improve the outcomes and care delivered to African Americans with myeloma; a disease with double the incidence in African Americans than Caucasians. Dr. Mikhael also spends about 20% of his time in the third world seeking ways to enhance research, collaboration and access to myeloma therapies in underprivileged countries.

Statement of Need

The incidence of, and death from, multiple myeloma (MM) is 50% more in men than in women and over twice among Black people compared with White people, in spite of the fact that Black patients are more likely than White patients to have MM with a favorable risk profile. Much of these disparities in outcomes can be mitigated by providing equitable access to therapy. Among data from 9 previously published clinical trials in patients with newly diagnosed MM, adverse demographic and clinical factors were associated with inferior survival, but race was not. One of the key access points to evidence-based medicine is clinical trials, and unfortunately, non-White patients are underrepresented in clinical trials. As such, greater enrollment of non-White patients into clinical trials needs to be a priority. While there are significant disparities in MM incidence and outcomes among patients of different racial-ethnic groups, clinicians can help reduce this disparity by improving access to evidence-based medicine, including triplet therapies, stem cell transplants, CAR T-cell therapies, and clinical trials.

In this CME Outfitters podcast, expert faculty will review recent data and discuss the sweeping impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma. This program will set the stage for intervention, empowering attendees to recognize and consider factors to improve multiple myeloma treatment.

Learning Objectives

At the end of this CME/CE activity, participants should be able to identify and describe the influence of bias, disparities, and inequities on multiple myeloma care.

Financial Support

Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and dietitians, specializing in oncology, hematology, or involved in treating patients with multiple myeloma

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-25-015-H01-P

Physician Assistants (AAPA): 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

Dietetics (CDR)

Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour = 1 CPEU). RDs and DTRs are to select activity type 102 in their Activity Log. Performance indicator selection is at the learner’s discretion.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.


Dr. Mitchell reports the following financial relationships:

  • Advisory Board: Corvus Pharmaceuticals, Inc.
  • Consultant: Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Genentech, Inc.; and SEMA4 OpCo, Inc.

Dr. Mikhael reports the following financial relationships:

  • Consultant: Amgen Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Jeffrey Helfand, DO (peer reviewer)
  • Meghann Taft-Lockhard (planning committee)
  • David Modrak, PhD (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

PD-085-101122-57

Racial and Ethnic Disparities and Health Inequities in Multiple Myeloma
Event Date: 10/11/2022 at 4:00 am EST